DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
ARN-509 is an investigational drug.
There have been 37 clinical trials for ARN-509. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2020.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Carcinoma. The leading clinical trial sponsors are Janssen Scientific Affairs, LLC, Aragon Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are forty US patents protecting this investigational drug and four hundred and seventy-five international patents.
Recent Clinical Trials for ARN-509
|Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer||National Cancer Institute (NCI)||Phase 3|
|Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer||NRG Oncology||Phase 3|
|A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)||Janssen Research & Development, LLC||Phase 4|
Top disease conditions for ARN-509
Top clinical trial sponsors for ARN-509
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ARN-509||Start Trial||Substituted thiohydantoin derivatives as androgen receptor antagonists||Janssen Pharmaceutica NV (Beerse, BE)||Start Trial|
|ARN-509||Start Trial||Androgen receptor modulators and uses thereof||Aragon Pharmaceuticals, Inc. (San Diego, CA)||Start Trial|
|ARN-509||Start Trial||Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer||Aragon Pharmaceuticals, Inc. (San Diego, CA)||Start Trial|
|ARN-509||Start Trial||Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof||The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|ARN-509||Start Trial||System and method for diagnosis and treatment||Pop Test Oncology Limited Liability Company (Cliffside Park, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|